Sandoz Biosimilar Wins Support From FDA Staff
U.S. Food and Drug Administration staff on Monday recommended approval of Sandoz Inc.'s biosimilar version of Amgen Inc.'s blockbuster biologic Neupogen, a milestone that marks the first such endorsement under an...To view the full article, register now.
Already a subscriber? Click here to view full article